APX 2039
Alternative Names: APX-2039; APX-2096Latest Information Update: 07 Feb 2024
At a glance
- Originator Amplyx Pharmaceuticals
- Developer Amplyx Pharmaceuticals; Duke University of North Carolina
- Class Antifungals; Small molecules
- Mechanism of Action GWT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cryptococcosis; Mycoses